Halozyme Therapeutics Inc (HALO.O)
27 Feb 2017
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|62||2016||Chairman of the Board|
|53||2014||President, Chief Executive Officer, Director|
|48||2015||Chief Financial Officer, Senior Vice President|
|53||2016||Chief Operating Officer, Senior Vice President|
|59||2015||Senior Vice President, Chief Compliance Officer, General Counsel|
- BRIEF-Halozyme Therapeutics Q4 loss per share $0.21
- BRIEF-First Eagle Investment Management LLC reports a 5.94 pct passive stake in Halozyme Therapeutics as of Dec 31 - SEC Filing
- BRIEF-Halozyme Therapeutics sees FY 2017 revenue $115 mln to $130 mln
- BRIEF-Halozyme sees FY 2017 revenue $115 mln to $130 mln
- Halozyme's pancreatic cancer drug succeeds in mid-stage trial